Clinical trial
An Observational Post-authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (XARELTO®) Initiated in Secondary Care for the Prevention of Atherothrombotic Events in Patients Who Have Had Acute Coronary Syndrome in England and Wales
NCT02673437 is registered in ClinicalTrials.gov with Drug Safety Research Unit, Southampton, UK as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Observational Post-authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (XARELTO®) Initiated in Secondary Care for the Prevention of Atherothrombotic Events in Patients Who Have Had Acute Coronary Syndrome in England and Wales
- Lead sponsor
- Drug Safety Research Unit, Southampton, UK
- Phase
- Observational
- Overall status
- Completed
- Start date
- September 30, 2015
- Completion date
- February 28, 2019
- Enrollment
- 701 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.